Biologicals and Biosimilars: Safety Issues in Europe

Expert Opinion on Biological Therapy - United Kingdom
doi 10.1080/14712598.2017.1330409
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

The Cost-Effectiveness of Periodic Safety Update Reports (PSURS) for Biologicals in Europe

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Php129 - Challenges and Opportunities in the Biologicals-Biosimilars Market: Sustainability and Market Differentiation

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Biosimilars: Ensuring Safety in the Search for Savings

Prescriber
Pharmacology
2017English

eParticipation Issues in Contemporary Europe

European Journal of Interdisciplinary Studies
2015English

The Impact of the Entry of Biosimilars: Evidence From Europe

Review of Industrial Organization
ManagementEconomicsOrganizational BehaviorHuman Resource ManagementStrategyInnovationManagement of TechnologyEconometrics
2018English

Safety-Related Regulatory Actions for Biologicals Approved in the United States and the European Union

JAMA - Journal of the American Medical Association
Medicine
2008English

Food Safety Issues in Canada

Northeastern Journal of Agricultural and Resource Economics
1990English

Evaluation of Physicians’ Knowledge and Attitudes Towards Biosimilars in Russia and Issues Associated With Their Prescribing

Biomolecules
BiochemistryMolecular Biology
2019English

Medical and Social Issues of Child Refugees in Europe

Archives of Disease in Childhood
Child HealthPediatricsPerinatology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy